Sanofi registers three-country OPTIMUS RISK cardiovascular cohort studies in ASCVD patientsOct 30Weekly roundup, 6 itemsfitusiranlunsekimigUpdated
Sanofi's NKCE trial SAR443579 in AML halted early; results posted for terminated studyOct 23Weekly roundup, 6 itemsBayerdiclofenac
Regeneron and Sanofi expand antibody collaboration to four new assetsOct 6Quarterly updateRegeneron PharmaceuticalsSanofi
Sanofi registers Phase 3 extension study for lunsekimig in COPD, named COLOSSUSAug 28Trial updatelunsekimigSanofi